Bruker (BRKR) Aandelenoverzicht
Bruker Corporation ontwikkelt, produceert en distribueert samen met zijn dochterondernemingen wetenschappelijke instrumenten en analytische en diagnostische oplossingen. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 5/6 |
| Toekomstige groei | 3/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 3/6 |
| Dividenden | 0/6 |
BRKR Community Fair Values
Create NarrativeSee what 28 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Bruker Corporation Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$59.71 |
| 52 Week Hoogtepunt | US$64.54 |
| 52 Week Laag | US$28.53 |
| Bèta | 1.3 |
| 1 maand verandering | 1.39% |
| 3 maanden verandering | 65.49% |
| 1 Jaar Verandering | 42.51% |
| 3 jaar verandering | -17.90% |
| 5 jaar verandering | -23.55% |
| Verandering sinds IPO | 158.91% |
Recent nieuws en updates
Narratiefupdate • Jun 26
BRKR: Rich Multiple And Execution Risks Will Pressure Earnings Power Into 2026
Bruker’s analyst fair value estimate has been revised from $36.80 to $35.00 as analysts weigh a richer valuation, even as several recent price target increases in the $60 to $65 range cite updated models and improving sentiment toward life science and diagnostic tools stocks. Analyst Commentary Recent Street commentary on Bruker shows a clear divide between optimistic targets and more cautious views that question how much upside is left at current prices.
Narratiefupdate • Jun 11
BRKR: Semiconductor And Diagnostics Momentum Will Balance Helium And Execution Risks
The updated analyst price target for Bruker has moved from an implied fair value of $49.15 to $53.25, reflecting recent target hikes into the $65 range by several firms as analysts incorporate refreshed models, sector sentiment, and valuation concerns into their views. Analyst Commentary Recent research updates show a mix of optimism and caution around Bruker, with price targets clustering around US$65 alongside more neutral stances that focus on valuation and operating risks.Recent updates
Narratiefupdate • Jun 26
BRKR: Rich Multiple And Execution Risks Will Pressure Earnings Power Into 2026
Bruker’s analyst fair value estimate has been revised from $36.80 to $35.00 as analysts weigh a richer valuation, even as several recent price target increases in the $60 to $65 range cite updated models and improving sentiment toward life science and diagnostic tools stocks. Analyst Commentary Recent Street commentary on Bruker shows a clear divide between optimistic targets and more cautious views that question how much upside is left at current prices.Narratiefupdate • Jun 11
BRKR: Semiconductor And Diagnostics Momentum Will Balance Helium And Execution Risks
The updated analyst price target for Bruker has moved from an implied fair value of $49.15 to $53.25, reflecting recent target hikes into the $65 range by several firms as analysts incorporate refreshed models, sector sentiment, and valuation concerns into their views. Analyst Commentary Recent research updates show a mix of optimism and caution around Bruker, with price targets clustering around US$65 alongside more neutral stances that focus on valuation and operating risks.Narratiefupdate • May 28
BRKR: Rising Helium Costs Will Constrain Earnings Power Into 2026
Analysts have lifted their average price target on Bruker by about $1.80, citing updated assumptions that include a slightly lower discount rate, modestly higher revenue growth and profit margin expectations, and a lower future P/E multiple. Analyst Commentary Recent Street research on Bruker reflects a mix of optimism on long term prospects and concern about near term risks.Narratiefupdate • May 14
BRKR: 2026 Earnings Delivery Will Outweigh Helium Cost Headwinds
Bruker's updated analyst price target has shifted to $49.15 from $47.86, as analysts factor in moderate adjustments to discount rates, revenue growth, profit margins and expected future P/E multiples, following a mix of recent target raises and cuts across the Street. Analyst Commentary Recent research on Bruker reflects a split view, with some analysts lifting price targets and others trimming them, as they reassess valuation, execution risk and potential headwinds in key input costs.Narratiefupdate • Apr 29
BRKR: Helium Cost Pressures And Margin Execution Will Shape 2026 Path
Analysts have trimmed their average price targets on Bruker by several dollars to reflect helium cost headwinds, recent margin pressure and lower valuation multiples, while underlying long term revenue growth and profit margin assumptions remain broadly consistent. Analyst Commentary Bearish analysts have been resetting expectations on Bruker, with several firms cutting price targets by mid single digit to low double digit dollar amounts.Narratiefupdate • Apr 15
BRKR: Rising Helium Costs Will Pressure Margins And Test 2026 Earnings
Analysts have reduced their Bruker price targets by mid single digit dollar amounts, citing lower margin expectations, helium related cost headwinds and revised sector multiples. These factors, in turn, feed into a higher implied future P/E and modest adjustments to growth and discount rate assumptions.Narratiefupdate • Apr 01
BRKR: 2026 Earnings Framework And Helium Risk Will Shape Future P/E
Bruker's updated analyst price target edges lower to about $48 per share, as analysts trim fair value and future P/E assumptions while factoring in helium cost risks and recent price target resets across the coverage group. Analyst Commentary Recent Street research on Bruker reflects a mix of optimism around long term growth targets and caution around nearer term execution, margins, and input cost risks.Seeking Alpha • Mar 31
Bruker: A Better, Yet Speculative Proposition
Summary Bruker's shares have declined 40% since January, pressured by weak 2025 results and a cautious 2026 outlook. 2025 saw organic sales decline 4%, high leverage (~3x), and significant M&A activity, raising concerns about capital allocation. 2026 guidance calls for modest 4–5% sales growth, 1–2% organic, and adjusted EPS of $2.10–$2.15, lowering valuation to 15–16x earnings. While conviction remains low due to uneven execution, the risk-reward is improving, warranting consideration of a small speculative position on further dips. Read the full article on Seeking AlphaNarratiefupdate • Mar 18
BRKR: 2026 Earnings Framework And Spatial Biology Expansion Will Support Higher P/E
Analysts have reduced the average Bruker price target to about $48, citing helium cost headwinds, a Q4 margin miss and lower sector valuation multiples, while noting that longer term earnings expectations remain in place. Analyst Commentary Research commentary on Bruker highlights a mix of optimism on long term earnings power and caution around near term execution risks and input costs, particularly helium.Narratiefupdate • Mar 03
BRKR: Reset Margins And 2026 Outlook Will Support Higher Forward P/E
Analysts have reset their view on Bruker, trimming the target to about $48 from about $54 as they factor in recent Q4 margin pressure, higher assumed discount rates and lower profit margin expectations. This comes even as revenue growth forecasts and future P/E assumptions move higher and Street research shows a mix of price target cuts and raises across firms.Narratiefupdate • Feb 17
BRKR: Future Earnings Reset Will Test 2026 Margin Ramp Assumptions
Analysts have trimmed their fair value estimate for Bruker to $35 from $38, reflecting lower applied multiples on future earnings targets after recent price target cuts across several firms, even as updated assumptions factor in changes to revenue growth and profit margins. Analyst Commentary Recent Street research around Bruker has turned more mixed, with several bearish analysts cutting price targets after the latest quarterly update, even as some firms maintain positive ratings or modestly higher targets.Analyseartikel • Feb 15
Analysts Have Been Trimming Their Bruker Corporation (NASDAQ:BRKR) Price Target After Its Latest Report
It's been a sad week for Bruker Corporation ( NASDAQ:BRKR ), who've watched their investment drop 13% to US$36.51 in...Narratiefupdate • Feb 03
BRKR: Q4 Setup And BEST Agreements Will Support Higher Forward P/E Multiple
Analysts have lifted their price targets on Bruker by amounts such as $5, $13 and to $53, citing updated views on the life science tools sector and Q4 setups. This feeds into our slightly higher fair value estimate and revised assumptions for discount rate, revenue growth, profit margin and future P/E.Narratiefupdate • Jan 20
BRKR: Constructive Bookings And Rating Upgrade Will Support Higher Forward P E Multiple
Analysts have lifted their Bruker price target to about $54 from about $52, citing slightly higher fair value estimates and modest adjustments to the discount rate, margin assumptions, and future P/E expectations. These changes are supported by a series of recent target hikes and an upgrade to Hold in the life science tools peer group.Narratiefupdate • Jan 06
BRKR: Constructive Bookings And Rating Upgrade Will Shape Balanced Forward Expectations
Analysts have raised their price target on Bruker by about US$0.57 to around US$52.36, reflecting updated views that factor in steadier bookings and the recent shift from Sell to Hold in Street ratings. Analyst Commentary Recent Street research on Bruker reflects a more balanced stance, with some analysts turning less negative while still highlighting execution risks and guidance concerns.Narratiefupdate • Dec 17
BRKR: Constructive Bookings And Rating Upgrade Will Support Stronger Forward Expectations
Analysts have modestly raised their price target on Bruker to about $52 from roughly $49, citing constructive bookings trends that help offset the impact of a 2025 guidance cut and support a slightly higher long term growth and valuation outlook. Analyst Commentary Analyst reactions to Bruker reflect a balanced mix of optimism and caution, with modest target price increases and a shift in ratings signaling improving sentiment but also recognition of execution and guidance risks.Narratiefupdate • Dec 03
BRKR: Constructive Bookings And Rating Upgrades Will Support Stable Forward Expectations
Analysts have modestly increased their price target on Bruker to approximately $49 from about $48, citing constructive bookings despite 2025 guidance cuts and recent upgrades in rating outlook. Analyst Commentary Analyst reactions to Bruker’s updated outlook highlight a more balanced risk and reward profile, with some modest upward revisions to valuation targets despite tempered near term expectations.Analyseartikel • Nov 26
Bruker Corporation's (NASDAQ:BRKR) Shares Bounce 26% But Its Business Still Trails The Industry
Bruker Corporation ( NASDAQ:BRKR ) shares have continued their recent momentum with a 26% gain in the last month alone...Narratiefupdate • Nov 19
BRKR: Booking Momentum Will Improve Sentiment Despite Lowered 2025 Outlook
Analysts have modestly increased their price target for Bruker from $40 to $43, citing more constructive bookings and improved financial metrics, even though 2025 guidance has been lowered. Analyst Commentary Recent analyst updates reflect a complex view of Bruker's prospects, with nuanced shifts in expectations tied to the company's latest financial disclosures and forward guidance.Narratiefupdate • Nov 03
BRKR: Recent Upgrade Will Drive Confidence In Core Market Resilience
Narrative Update: Bruker Analyst Price Target Increased Analysts have raised Bruker's fair value price target by approximately $1.09 to $47.82, citing improved ratings and updated market assessments, even as growth expectations have moderated slightly. Analyst Commentary Bullish Takeaways Bullish analysts note that the recent price target increase reflects greater confidence in Bruker’s ability to deliver stable financial results in the near term.Analyseartikel • Aug 10
Why Investors Shouldn't Be Surprised By Bruker Corporation's (NASDAQ:BRKR) 31% Share Price Plunge
NasdaqGS:BRKR 1 Year Share Price vs Fair Value Explore Bruker's Fair Values from the Community and select yours The...Narratiefupdate • Aug 06
Renewed Biopharma Funding And Cost Savings Will Revitalize Markets
Bruker's consensus analyst price target has declined notably, primarily due to weaker revenue growth forecasts and a lower forward P/E multiple, resulting in a reduced fair value estimate of $46.73. What's in the News Bruker provided guidance for FY2025, projecting revenues of $3.43-$3.50 billion (2%-4% reported growth), driven mainly by M&A (3.5%) and FX tailwind (2.5%), but expects 2%-4% organic revenue decline; Q2 2025 revenue is projected to be approximately flat year-over-year at $795-$798 million (Key Developments).Rendement voor aandeelhouders
| BRKR | US Life Sciences | US Markt | |
|---|---|---|---|
| 7D | 8.3% | 9.8% | 0.3% |
| 1Y | 42.5% | 17.2% | 19.9% |
Rendement versus industrie: BRKR overtrof de US Life Sciences industrie, die het afgelopen jaar een rendement 17.2 % opleverde.
Rendement versus markt: BRKR overtrof de US markt, die het afgelopen jaar een rendement opleverde van 19.9 %.
Prijsvolatiliteit
| BRKR volatility | |
|---|---|
| BRKR Average Weekly Movement | 8.7% |
| Life Sciences Industry Average Movement | 8.7% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: BRKR heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 9% ) van BRKR is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1960 | 11,085 | Frank Laukien | www.bruker.com |
Bruker Corporation ontwikkelt, produceert en distribueert, samen met zijn dochterondernemingen, wetenschappelijke instrumenten en analytische en diagnostische oplossingen. Het bedrijf is actief via vier segmenten: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, en Bruker Energy & Supercon Technologies. Het bedrijf biedt magnetische resonantie spectroscopie, preklinische beeldvorming, biofarma en toegepaste, diensten en levenscyclusondersteuning, geïntegreerde data-oplossing en automatisering; life science tools; innovatieve nucleaire magnetische resonantie (NMR) en elektronen paramagnetische resonantie (EPR) producten; oplossingen voor in-vivo processen en drug discovery; aftermarket-oplossingen; oplossingen voor labautomatisering en digitalisering; massaspectrometrie-oplossingen en testkits, DNA-teststrips en op fluorescentie gebaseerde PCR-technologieën; genotype en fluorotype moleculaire diagnostische kits; en instrumenten en oplossingen voor onderzoek, analyse en procesanalyse.
Bruker Corporation Samenvatting
| BRKR fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$9.09b |
| Inkomsten(TTM) | -US$36.40m |
| Inkomsten(TTM) | US$3.46b |
2.6x
P/S-verhouding-249.7x
Koers/WinstverhoudingIs BRKR overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| BRKR resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$3.46b |
| Kosten van inkomsten | US$1.81b |
| Brutowinst | US$1.65b |
| Overige uitgaven | US$1.68b |
| Inkomsten | -US$36.40m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -0.24 |
| Brutomarge | 47.62% |
| Nettowinstmarge | -1.05% |
| Schuld/Eigen Vermogen Verhouding | 67.4% |
Hoe presteerde BRKR op de lange termijn?
Bekijk historische prestaties en vergelijkingDividenden
0.3%
Huidig dividendrendement-83%
UitbetalingsratioBetaalt BRKR een betrouwbaar dividend?
Zie BRKR dividendgeschiedenis en benchmarks| Bruker dividenddata | |
|---|---|
| Ex Dividend Datum | Jun 22 2026 |
| Betaaldatum dividend | Jul 07 2026 |
| Dagen tot Ex-dividend | 9 days |
| Dagen tot dividendbetaaldatum | 6 days |
Betaalt BRKR een betrouwbaar dividend?
Zie BRKR dividendgeschiedenis en benchmarksBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/06/30 19:45 |
| Aandelenkoers aan het einde van de dag | 2026/06/29 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Bruker Corporation wordt gevolgd door 29 analisten. 12 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Luke Sergott | Barclays |
| Michael Ryskin | BofA Global Research |
| Paul Knight | Brean Capital Historical (Janney Montgomery) |